These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36630616)

  • 1. Bivalent Covid-19 Vaccines - A Cautionary Tale.
    Offit PA
    N Engl J Med; 2023 Feb; 388(6):481-483. PubMed ID: 36630616
    [No Abstract]   [Full Text] [Related]  

  • 2. Stroke, Myocardial Infarction, and Pulmonary Embolism after Bivalent Booster.
    Jabagi MJ; Bertrand M; Botton J; Le Vu S; Weill A; Dray-Spira R; Zureik M
    N Engl J Med; 2023 Apr; 388(15):1431-1432. PubMed ID: 36988584
    [No Abstract]   [Full Text] [Related]  

  • 3. A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2.
    Yuan Y; Zhang X; Chen R; Li Y; Wu B; Li R; Zou F; Ma X; Wang X; Chen Q; Deng J; Zhang Y; Chen T; Lin Y; Yan S; Zhang X; Li C; Bu X; Peng Y; Ke C; Deng K; Pan T; He X; Zhang Y; Zhang H
    Cell Rep; 2022 Jan; 38(3):110256. PubMed ID: 34990583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Audio Interview: Assessing Bivalent Vaccines against Covid-19.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2022 Sep; 387(13):e37. PubMed ID: 36170506
    [No Abstract]   [Full Text] [Related]  

  • 5. Neutralization of BA.4-BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine.
    Zou J; Kurhade C; Patel S; Kitchin N; Tompkins K; Cutler M; Cooper D; Yang Q; Cai H; Muik A; Zhang Y; Lee DY; Şahin U; Anderson AS; Gruber WC; Xie X; Swanson KA; Shi PY
    N Engl J Med; 2023 Mar; 388(9):854-857. PubMed ID: 36734885
    [No Abstract]   [Full Text] [Related]  

  • 6. Options for the development of a bivalent vaccine against SARS-CoV-2 and influenza.
    Stepanova E; Isakova-Sivak I; Rudenko L
    Expert Rev Vaccines; 2022 Nov; 21(11):1533-1535. PubMed ID: 36004567
    [No Abstract]   [Full Text] [Related]  

  • 7. Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection - Increasing Community Access to Testing Program, United States, September-November 2022.
    Link-Gelles R; Ciesla AA; Fleming-Dutra KE; Smith ZR; Britton A; Wiegand RE; Miller JD; Accorsi EK; Schrag SJ; Verani JR; Shang N; Derado G; Pilishvili T
    MMWR Morb Mortal Wkly Rep; 2022 Dec; 71(48):1526-1530. PubMed ID: 36454688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of mRNA-Based Vaccines for SARS CoV-2.
    Barda B; Cerny A
    Chem Res Toxicol; 2021 Aug; 34(8):1823-1825. PubMed ID: 34009959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2 Antibody Responses to the Ancestral SARS-CoV-2 Strain and Omicron BA.1 and BA.4/BA.5 Variants in Nursing Home Residents After Receipt of Bivalent COVID-19 Vaccine - Ohio and Rhode Island, September-November 2022.
    Canaday DH; Oyebanji OA; White EM; Bosch J; Nugent C; Vishnepolskiy I; Abul Y; Didion EM; Paxitzis A; Sundheimer N; Ragavapuram V; Wilk D; Keresztesy D; Cao Y; St Denis K; McConeghy KW; McDonald LC; Jernigan JA; Mylonakis E; Wilson BM; King CL; Balazs AB; Gravenstein S
    MMWR Morb Mortal Wkly Rep; 2023 Jan; 72(4):100-106. PubMed ID: 36701254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.
    Lim HX; Arip M; Yahaya AAA; Jazayeri SD; Poppema S; Poh CL
    Front Biosci (Landmark Ed); 2021 Nov; 26(11):1286-1304. PubMed ID: 34856768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunologic Effect of Bivalent mRNA Booster in Patients Undergoing Hemodialysis.
    Huth L; Schäfer L; Almanzar G; Lupoli G; Bischof M; Wratil PR; Stövesand T; Drechsler C; Keppler OT; Prelog M
    N Engl J Med; 2023 Mar; 388(10):950-952. PubMed ID: 36791308
    [No Abstract]   [Full Text] [Related]  

  • 12. A Bivalent Omicron-Containing Booster Vaccine against Covid-19.
    Chalkias S; Harper C; Vrbicky K; Walsh SR; Essink B; Brosz A; McGhee N; Tomassini JE; Chen X; Chang Y; Sutherland A; Montefiori DC; Girard B; Edwards DK; Feng J; Zhou H; Baden LR; Miller JM; Das R
    N Engl J Med; 2022 Oct; 387(14):1279-1291. PubMed ID: 36112399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19 vaccines for patients with haematological conditions.
    Sun C; Pleyer C; Wiestner A
    Lancet Haematol; 2021 May; 8(5):e312-e314. PubMed ID: 33811822
    [No Abstract]   [Full Text] [Related]  

  • 14. Immune thrombocytopenic purpura after SARS-CoV-2 vaccine.
    Candelli M; Rossi E; Valletta F; De Stefano V; Franceschi F
    Br J Haematol; 2021 Aug; 194(3):547-549. PubMed ID: 33934330
    [No Abstract]   [Full Text] [Related]  

  • 15. The Century of mRNA Vaccines: COVID-19 Vaccines and Allergy.
    Ortega Rodríguez NR; Audícana Berasategui MT; de la Hoz Caballer B; Valero Santiago A
    J Investig Allergol Clin Immunol; 2021 Feb; 31(1):89-91. PubMed ID: 33393485
    [No Abstract]   [Full Text] [Related]  

  • 16. Cross-variant protection against SARS-CoV-2 infection in hamsters immunized with monovalent and bivalent inactivated vaccines.
    Ye ZW; Fan Y; Tang K; Ong CP; Luo C; Chung HL; Leong TL; Liang R; Lui WY; Zhou R; Cheng Y; Lu L; Cheung PH; Chan JF; Chen Z; Yuen KY; Yuan S; To KK; Jin DY
    Int J Biol Sci; 2022; 18(12):4781-4791. PubMed ID: 35874942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer and COVID-19 vaccines: a complex global picture.
    Yusuf A; Sarfati D; Booth CM; Pramesh CS; Lombe D; Aggarwal A; Bhoo-Pathy N; Tsunoda A; Vanderpuye V; Kutluk T; Sullivan A; Mukherji D; Mutebi M; van Hemelrijck M; Sullivan R;
    Lancet Oncol; 2021 Jun; 22(6):749-751. PubMed ID: 33930324
    [No Abstract]   [Full Text] [Related]  

  • 18. India begins COVID-19 vaccination amid trial allegations.
    Bhuyan A
    Lancet; 2021 Jan; 397(10271):264. PubMed ID: 33485435
    [No Abstract]   [Full Text] [Related]  

  • 19. mRNA Vaccines against SARS-CoV-2: Advantages and Caveats.
    Echaide M; Chocarro de Erauso L; Bocanegra A; Blanco E; Kochan G; Escors D
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36983017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination of patients with inflammatory rheumatic diseases against SARS-CoV-2: considerations before widespread availability of the vaccines.
    Schulze-Koops H; Specker C; Skapenko A
    RMD Open; 2021 Feb; 7(1):. PubMed ID: 33627439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.